Media & news

The Annual General Meeting of Nobel Biocare approves all proposals of the Board of Directors

Nobel Biocare Holding AG’s Annual General Meeting today endorsed all proposals put forward by the Board of Directors.

Among others, the Annual General Meeting approved a dividend of CHF 0.20 gross per registered share of CHF 0.40 nominal value. The dividend will be paid on April 2, 2014 (ex-dividend day: March 28, 2014; record date: April 1, 2014) in a shareholder-friendly way without deduction of withholding tax.

The next Annual General Meeting of the shareholders will be convened on March 25, 2015.

Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.